
Grünenthal Group to acquire Almirall’s Mexico unit for about €50 million
pharmafile | March 17, 2016 | News story | Business Services, Sales and Marketing | Almirall, Grünenthal Group, merger and acquisition
Privately-held Grünenthal Group said it has signed a definitive agreement to buy Almirall Group’s Mexico-based business for about €50 million ,to enter into the gastroenterology segment and expand its pain portfolio.
Under the terms of the deal, Germany-based Grünenthal will buy 100% of Almirall’s Mexico unit to for €30 million . In addition, the company has agreed a perpetual license deal for its products in Mexico for €20 million.
Eric-Paul Pâques, chief executive of Grünenthal, says: “It is a clear part of our strategy to continuously invest and significantly expand our presence in Latin America. The acquisition of Almirall de Mexico is a very important step towards our objective and we are very excited about the joint potential of the two companies, which will allow us to be positioned amongst the top pharmaceutical companies in Mexico.”
The transaction will be completed in early May, 2016, the company said in a statement.
Oscar Ferenczi, executive vice president Grünenthal Latin America, says: “Mexico is one of the top markets in Latin America, and we are very excited to be able to offer our customers and the patients soon a larger portfolio to help address their needs.”
Anjali Shukla
Related Content

Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment
Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk …

Almirall gains EC approval of Ebglyss for moderate-to-severe atopic dermatitis
Almirall has announced that the European Commission (EC) has approved Ebglyss (lebrikizumab) for the treatment …
Almirall: The New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD) publish Ph3 data evaluating lebrikizumab efficacy and safety in moderate-to-severe atopic dermatitis
BARCELONA, Spain. March 31, 2023 – Almirall, S.A. (ALM), a global biopharmaceutical company focused on …






